Carbon Biosciences is the first company to publicly launch from the Foundation’s collaboration with Longwood Fund and the first to work alongside CF Foundation researchers at the Foundation’s therapeutics lab
Site Search
Showing 1 - 4 of 4 results
Press Release
|
June 21, 2022
|
4 min read
The funding will help support research into the development of potential new modulator therapies for people with cystic fibrosis with an F508del mutation.
News
|
March 7, 2024
|
2 min read
Funding will support a Phase 2b trial of phage therapy for chronic Pseudomonas aeruginosa lung infections.
News
|
March 18, 2024
|
2 min read
The additional funding will support a Phase 2 clinical trial for an inhaled antisense oligonucleotide drug for people with cystic fibrosis who have the splicing mutation 3849+10Kb C-to-T.
Press Release
|
April 3, 2024
|
3 min read